In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology

Area of Science:

• Oncology
• Biotechnology
• Pharmacology

Background:

• Multiple myeloma, a plasma cell neoplasm, lacks predictive markers for drug response.
• Current treatments require better methods to personalize therapy based on individual patient needs.

Purpose of the Study:

• To evaluate Cellply CC-Array® technology for high-throughput in vitro drug response analysis in multiple myeloma.
• To explore its utility as a predictive marker for patient treatment outcomes and effector cell effectiveness.

Main Methods:

• Mononuclear cells from 22 multiple myeloma patients' bone marrow were analyzed using Cellply CC-Array® technology.
• In vitro drug responses to melphalan, bortezomib, and dexamethasone were assessed.
• Effector cell anti-tumor activity was evaluated through cell proximity analysis.

Main Results:

• In vitro drug responses to melphalan, bortezomib, and dexamethasone correlated with patient clinical responses.
• The technology showed limitations with lenalidomide, daratumumab, and elotuzumab due to in vitro myeloma cell viability.
• The platform successfully assessed anti-tumor activity of NK and T cells.

Conclusions:

• Cellply CC-Array® microwell technology can assess in vitro myeloma cell responses to specific therapies.
• Further validation with larger cohorts is needed to confirm in vitro-in vivo outcome correlations.
• This technology shows promise for predicting treatment outcomes and evaluating immune cell function in multiple myeloma.